Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized heparin for ventilator-free days in ICU patients with acute respiratory distress syndrome
IRCT20211010052718N2Phase 3Completed
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- Apr 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of heparin in acute respiratory distress syndrome (ARDS) (2 arms), sponsored by Mazandaran University of Medical Sciences. Primary endpoint: Ventilator-free days. Started Apr 2022; status: completed.
02
Drugs
heparin
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on IRCT20211010052718N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211010052718N2.